双龙抗纤胶囊治疗结缔组织病肺纤维化临床研究  

Clinical study of Shuanglong Antifiber Capsule for pulmonary fibrosis in connective tissue disease

作　　者：徐强[1] 钮含春[1] 霍泉金[1] 李晓云[1] XU Qiang;NIU Hanchun;HUO Quanjin;LI Xiaoyun(Department of Rheumatology,Shijiazhuang Pingan Hospital,Hebei Medical University,Shijiazhuang,Hebei 050021)

机构地区：[1]河北医科大学附属石家庄平安医院风湿病科,河北石家庄050021

出　　处：《河北中医》2022年第2期204-209,214,共7页Hebei Journal of Traditional Chinese Medicine

基　　金：河北省中医药管理局2019年度中医药类科研计划课题(编号:2019423)。

摘　　要：目的观察双龙抗纤胶囊治疗结缔组织病(CTD)肺纤维化的临床疗效。方法将80例CTD肺纤维化患者按照随机数字表法分为2组,2组均予基础治疗,对照组40例(后退出2例)予安慰剂治疗,治疗组40例(后退出2例)予双龙抗纤胶囊口服。2组均治疗12周。比较2组治疗前后中医证候评分、肺功能[肺总量(TLC)占预计值百分比、肺活量(VC)占预计值百分比、肺一氧化碳弥散量(DLCO)占预计值百分比]、血气分析{动脉氧分压[p(O_(2))]、血氧饱和度(SaO_(2))、二氧化碳分压[p(CO_(2))]、肺部高分辨率CT(HRCT)评分},并统计2组疗效。结果治疗组总有效率84.21%(32/38),对照组总有效率63.16%(24/38),治疗组疗效优于对照组(P<0.05)。2组治疗后中医证候各项评分及总分均较本组治疗前降低(P<0.05),且治疗组治疗后均低于对照组(P<0.05),治疗组治疗前后差值均高于对照组(P<0.05)。2组治疗后TLC、VC、DLCO占预计值百分比均较本组治疗前升高(P<0.05),且治疗组治疗后均高于对照组(P<0.05),治疗组治疗前后差值均高于对照组(P<0.05)。2组治疗后p(O_(2))、SaO_(2)均较本组治疗前升高(P<0.05),p(CO_(2))均降低(P<0.05),且治疗组治疗后p(O_(2))、SaO_(2)均高于对照组(P<0.05),p(CO_(2))低于对照组(P<0.05),治疗组治疗前后差值均高于对照组(P<0.05)。2组治疗前后及治疗后组间HRCT评分比较差异均无统计学意义(P>0.05),2组治疗前后差值比较差异无统计学意义(P>0.05)。结论双龙抗纤胶囊治疗CTD肺纤维化取得一定的临床疗效,能明显改善患者肺功能、血气分析指标,安全性较好。Objective To observe the clinical efficacy of Shuanglong Antifiber Capsule(SAC)on pulmonary fibrosis in connective tissue disease(CTD).Methods Totally 80 CTD patients with pulmonary fibrosis were divided randomly into the treatment group(n=40,2 cases quit)and the control group(n=40,2 cases quit),apart from basal treatment,patients in the control group were managed by placebo,and those in the treatment group were additionally treated with oral SAC.Treated for 12 weeks,the aim was to compare traditional Chinese medicine(TCM)syndrome score,pulmonary function(the percentage of predicted total lung capacity[TLC],vital capacity[VC],carbon monoxide diffusion capacity[DLCO]),blood gas analysis including arterial oxygen pressure(p[O_(2)]),oxygen saturation(SaO_(2)),partial pressure of carbon dioxide(p[CO_(2)]);lung high resolution computed tomography(HRCT)score;the curative effect was counted.Results The overall effective rate was 84.21%(32/38)in the treatment group,higher than that of 63.16%(24/38)in the control group(P<0.05).After treatment,the TCM syndrome scores in groups were decreased(P<0.05),the treatment group was lower than the control group(P<0.05),and the differential value of TCM syndrome scores in the treatment group was higher than that in the control group(P<0.05);the percentage of predicted value of TLC,VC and DLCO in groups were increased(P<0.05),which increased in the treatment group compared with the control group(P<0.05),and the differential value in the treatment group was higher than that in the control group(P<0.05);p(O_(2))and SaO_(2) in groups were increased(P<0.05),the treatment group was higher than the control group(P<0.05),p(CO_(2))was decreased(P<0.05),the treatment group was more common(P<0.05),and the differential value in the treatment group was higher than that in the control group(P<0.05).The difference was not statistically significant in the HRCT scores between groups before and after treatment(P>0.05),and there was no significant difference in the differential value between groups bef

关 键 词：结缔组织疾病 肺纤维化 中药疗法 

分 类 号：R593.205.31[医药卫生—内科学]